GSK's Momelotinib Receives Orphan Drug Designations for Life-Threatening VEXAS Syndrome
GSK sits 50% above its 52-week low of $35.45.
Summary
GSK's momelotinib received Orphan Drug Designations from US and EU regulators for VEXAS syndrome, a rare and life-threatening condition with no approved treatments, supporting its advanced development.
Key Events · Product Development and Regulatory · GSK
-
Orphan Drug Designations Granted
Momelotinib received Orphan Drug Designation (ODD) from both the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) for the treatment of VEXAS syndrome.
-
Addresses High Unmet Medical Need
VEXAS syndrome is a rare, life-threatening haemato-inflammatory condition with a 30-40% five-year mortality rate and currently no approved treatment options.
-
Advanced Clinical Development
A planned Phase II/III ATLAS trial is underway to evaluate momelotinib's efficacy and safety in VEXAS syndrome, supporting future global regulatory submissions.
-
Existing Drug with Differentiated Mechanism
Momelotinib (Ojjaara/Omjjara) is already approved in the US, EU, UK, and Japan for myelofibrosis and has a differentiated mechanism of action.
Analysis · GSK · Life Sciences
The US FDA and EMA granting Orphan Drug Designations for momelotinib in VEXAS syndrome is a significant positive for GSK's pipeline. VEXAS is a rare, severe, and currently untreatable condition, meaning these designations provide regulatory support and potential market exclusivity for a drug addressing a high unmet medical need. The ongoing Phase II/III ATLAS trial will further evaluate momelotinib's potential in this indication.
How filings like this one have moved
In the 30 days to Sep 13, 2026, 35.6% of the 1216 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GSK was trading at $53.20 on NYSE in the Life Sciences sector, with a market capitalization of approximately $105.5B. The 52-week trading range was $35.45 to $61.70. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.